Tiffany Autry
Dermatology · Las Cruces, NMNPI 1003389875
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,368 of the $3,762 with a category attached, or 89.5%. 16 manufacturers reported payments, led by Johnson & Johnson at 27.4% of the total. 2025 is the largest year on record at $1,319, 8.9 times the $148 reported in 2021.
Across 142 payments — averaging $26.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Lilly USA, LLC$789
- Revance Therapeutics, Inc.$734
- AbbVie$519
- Galderma Laboratories, L.p.$189
- Pfizer$93
- plus $408 from 10 others
What the payments were for
- Food & beverage$3,36890%
- Education$39310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 37 | $1,030 |
| Lilly USA, LLC | 48 | $789 |
| Revance Therapeutics, Inc. | 9 | $734 |
| AbbVie(2 entities) | 15 | $519 |
| Galderma Laboratories, L.p. | 12 | $189 |
| Pfizer | 5 | $93 |
| Regeneron | 1 | $73 |
| E.r. Squibb & Sons, L.L.C. | 3 | $67 |
| Boehringer Ingelheim | 3 | $58 |
| UCB, Inc. | 2 | $55 |
| Organon | 2 | $44 |
| Novartis | 1 | $35 |
| Organogenesis Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Incyte Corporation | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAXXIFY$403
How this compares
$3,762 in reported general payments places this provider in the 85th percentile of 52 dermatology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 12 | $246,267 |
| Dupixent PenDupilumab | 25 | $97,478 |
| Taltz AutoinjectorIxekizumab | 13 | $92,955 |
| HumiraAdalimumab | 11 | $88,484 |
| Humira(Cf) PenAdalimumab | 12 | $85,009 |
| Clobetasol Propionate | 59 | $3,511 |
| Tretinoin | 20 | $2,829 |
| Calcipotriene | 12 | $2,458 |
| Fluorouracil | 26 | $2,038 |
| Ketoconazole | 88 | $1,529 |
| Metronidazole | 16 | $1,482 |
| Triamcinolone Acetonide | 151 | $1,232 |
| Doxycycline Hyclate | 29 | $1,126 |
| Clindamycin Phosphate | 19 | $808 |
| Betamethasone Valerate | 30 | $803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira | $519 | $88,48411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 52 dermatology providers in New Mexico.
Other dermatology in Las Cruces
- Andrew OndoLas Cruces$215K
- James KernerLas Cruces$4K
- Richard HempsteadLas Cruces$86
- John DurkinAlbuquerque$153K
- Barbara EinhornAlbuquerque$15K
- Carol PurcellAlbuquerque$9K
- Michaela JacobsAlbuquerque$7K
- Deeptej SinghAlbuquerque$5K
- Darren KemptonAlbuquerque$4K
- Catherine Tchanque-FossuoAlbuquerque$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.